Cervical cancer cell–derived angiopoietins promote tumor progression

Chemotherapy and molecular targeting therapy for recurrent cervical cancer

(2016) Naotake Tsuda et al.   Chinese Journal of Cancer Research

A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment

(2015) Robert S. Kerbel   CANCER JOURNAL

Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)

(2015) Claudia Marchetti et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Retrospective comparison of laparoscopic versus open radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer

(2015) Jing Cai et al.   INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)

(2015) Joanne W. Chiu et al.   INVESTIGATIONAL NEW DRUGS

Tie-1: A potential target for anti-angiogenesis therapy

(2015) Ping Yang et al.   Journal of Huazhong University of Science and Technology-Medical Sciences

Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240)

(2015) Richard T Penson et al.   LANCET ONCOLOGY

Endothelial destabilization by angiopoietin-2 via integrin β1 activation

(2015) Laura Hakanpaa et al.   Nature Communications

Gln-362 of Angiopoietin-2 Mediates Migration of Tumor and Endothelial Cells through Association with α5β1 Integrin

(2014) Hyo Seon Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Use of Laser Microdissection in the Identification of Suitable Reference Genes for Normalization of Quantitative Real-Time PCR in Human FFPE Epithelial Ovarian Tissue Samples

(2014) Jing Cai et al.   PLoS One

Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy

(2013) D. Gerald et al.   CANCER RESEARCH

Angiopoietin signaling in the vasculature

(2013) Lauri Eklund et al.   EXPERIMENTAL CELL RESEARCH

Angiopoietins in angiogenesis

(2012) Ernesta Fagiani et al.   CANCER LETTERS

Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling

(2012) Moritz Felcht et al.   JOURNAL OF CLINICAL INVESTIGATION

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Angiopoietin-2, an Angiogenic Regulator, Promotes Initial Growth and Survival of Breast Cancer Metastases to the Lung through the Integrin-linked Kinase (ILK)-AKT-B Cell Lymphoma 2 (Bcl-2) Pathway

(2011) Yorihisa Imanishi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Angiopoietin-2 Promotes Disease Progression of Neuroendocrine Tumors

(2010) K. M. Detjen et al.   CLINICAL CANCER RESEARCH

Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody

(2010) A. Coxon et al.   MOLECULAR CANCER THERAPEUTICS

PlGF expression in pre-invasive and invasive lesions of uterine cervix is associated with angiogenesis and lymphangiogenesis

(2009) SHOUHUA YANG et al.   APMIS

Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma

(2009) I. Helfrich et al.   CLINICAL CANCER RESEARCH

Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions

(2009) Hester van Cruijsen   Frontiers in Bioscience-Landmark

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

(2009) Hellmut G. Augustin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY